Cite this answer
Gonadorelin: quick citable summary
Gonadorelin is listed by PeptaHub as a sexual health peptide with a prescription legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Gonadorelin: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/gonadorelin. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/gonadorelin.
What is Gonadorelin?
Gonadorelin is a synthetic decapeptide identical to endogenous GnRH, used clinically via pulsatile pump to induce ovulation and to induce fertility in hypogonadotropic hypogonadism. It is widely used off-label alongside TRT to maintain testicular function, but no published trial has tested that use.
Overview
Gonadorelin is a synthetic decapeptide identical in structure to endogenous gonadotropin-releasing hormone (GnRH), produced naturally by the hypothalamus. It held FDA approval for diagnostic evaluation of pituitary function and, as a pump-delivered formulation, for inducing ovulation in primary hypothalamic amenorrhea; both products have since been withdrawn from the US market for commercial reasons. Its established clinical use depends on pulsatile pump delivery. The widespread off-label use alongside testosterone replacement to maintain testicular function is not supported by published trials.
Mechanism of action
Gonadorelin binds to GnRH receptors on pituitary gonadotrope cells, triggering the synthesis and pulsatile release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH stimulates Leydig cells in the testes to produce testosterone, while FSH supports Sertoli cells and spermatogenesis. The pulsatile pattern is critical — continuous administration causes receptor downregulation and desensitization, paradoxically suppressing gonadotropin output (the basis of GnRH agonist-based androgen deprivation therapy). When dosed correctly in pulses every 60–120 minutes, gonadorelin preserves the hypothalamic-pituitary-gonadal (HPG) axis feedback loop, maintaining intratesticular testosterone and sperm production even in men receiving exogenous testosterone.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| TRT testicular maintenance | subcutaneous | 100–100 mcg | 2-3x per week | This range reflects clinic and compounding-pharmacy practice, not trial data — no published study has evaluated gonadorelin for testicular preservation during TRT. The stated goal is LH/FSH stimulation to preserve testicular size and intratesticular testosterone, but that outcome has not been measured for this regimen. |
| Hypogonadotropic hypogonadism / fertility | subcutaneous | 5–20 mcg | Pulsatile, every 90-120 minutes via infusion pump | Delivered via portable infusion pump. Pulsatile dosing is essential — continuous exposure suppresses rather than stimulates. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert Gonadorelin research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? The Gonadorelin dose calculator is preloaded with these ranges, or use the general dose unit converter.
Research summary
The clinical evidence for gonadorelin is about pump-delivered pulsatile dosing. In women with hypothalamic amenorrhea, pulsatile GnRH induces ovulation reliably: a 25-year single-center cohort of 66 patients reported a 96% ovulation rate per cycle, monofollicular ovulation in 75% of cycles, and a low multiple-pregnancy rate (Quaas et al., 2022). In men with congenital hypogonadotropic hypogonadism, pulsatile GnRH via pump induces spermatogenesis and fertility (Dwyer et al., 2024). The popular off-label use — roughly 100 mcg subcutaneously two or three times a week alongside TRT to prevent testicular atrophy — has no published trial behind it. A PubMed search returns no study evaluating gonadorelin for testicular preservation during testosterone replacement, so claims about preserved testicular volume, intratesticular testosterone or fertility on this regimen are extrapolation. Note also that twice-weekly injection is not pulsatile dosing in the pharmacological sense the pump studies established.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Gonadorelin for synergistic effects.
Legal status
Two gonadorelin products held FDA approval: Factrel (gonadorelin HCl) for diagnostic evaluation of pituitary gonadotropic function, and Lutrepulse (gonadorelin acetate, pump-delivered) for induction of ovulation in women with primary hypothalamic amenorrhea. Both were withdrawn from the US market for commercial reasons, not for safety or efficacy, and no FDA-approved gonadorelin product is currently marketed in the United States. Hypogonadotropic hypogonadism in men was never an FDA-approved indication. US supply today is compounded, and use in TRT protocols is off-label.
Sourcing & access
Prescription required
Gonadorelin is an FDA-approved prescription medication available through licensed healthcare providers, pharmacies, and label-appropriate access programs; compounded access depends on current FDA shortage status and compounding rules.
Frequently asked questions
Gonadorelin is a synthetic decapeptide identical in structure to endogenous gonadotropin-releasing hormone (GnRH). It held FDA approval for diagnostic evaluation of pituitary function and, via pump, for ovulation induction in primary hypothalamic amenorrhea. Both approved products have been withdrawn from the US market for commercial reasons, and current US supply is compounded. Use in TRT protocols is off-label.
Gonadorelin binds GnRH receptors on pituitary gonadotrope cells, triggering LH and FSH release. LH stimulates testosterone production in Leydig cells, while FSH supports spermatogenesis. Pulsatile dosing is critical, as continuous exposure paradoxically suppresses gonadotropin output.
Side effects include injection site irritation, headache, nausea, flushing, and abdominal discomfort. The most important risk is receptor desensitization from continuous (non-pulsatile) dosing, which suppresses rather than stimulates hormone production.
Exogenous testosterone suppresses the HPG axis, causing testicular atrophy and infertility, and the rationale for adding gonadorelin is to keep LH and FSH signaling going. Be clear about the evidence: this is prescribing practice, not a studied regimen. No published trial has evaluated gonadorelin at 100 mcg two or three times weekly, or any other dose, for preserving testicular volume, intratesticular testosterone or fertility during TRT. The pulsatile pump dosing that established GnRH efficacy is also a different regimen from twice-weekly injection.
Gonadorelin acts upstream at the pituitary to stimulate LH release, while hCG directly mimics LH at the testicular level. The argument that gonadorelin better preserves the HPG axis is mechanistic reasoning, not a trial result: the two have never been compared head-to-head for fertility or testicular preservation during TRT, and hCG has the larger clinical evidence base.
Research references
- Clinical review 15: Management of ovulatory disorders with pulsatile gonadotropin-releasing hormoneReview
- Use of pulsatile gonadotropin-releasing hormone (GnRH) in patients with functional hypothalamic amenorrhea (FHA) results in monofollicular ovulation and high cumulative live birth rates: a 25-year cohortPubMed
- Current landscape of fertility induction in males with congenital hypogonadotropic hypogonadismReview
- Ovulation induction with pulsatile gonadotropin releasing hormone: missing in actionPubMed
- Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injectionPubMed